Dyne Therapeutics, Inc.
DYN
$18.29
-$0.37-1.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.25% | 29.66% | 70.69% | -35.31% | 73.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.59% | 7.79% | 60.91% | 76.95% | 43.46% |
| Operating Income | -19.59% | -7.79% | -60.91% | -76.95% | -43.46% |
| Income Before Tax | -25.03% | -11.24% | -70.28% | -75.72% | -34.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.03% | -11.24% | -70.28% | -75.72% | -34.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.03% | -11.24% | -70.28% | -75.72% | -34.37% |
| EBIT | -19.59% | -7.79% | -60.91% | -76.95% | -43.46% |
| EBITDA | -19.61% | -7.74% | -61.10% | -77.21% | -43.65% |
| EPS Basic | 13.62% | 20.87% | -38.34% | -29.58% | 19.11% |
| Normalized Basic EPS | 13.61% | 20.86% | -38.34% | -29.57% | 19.10% |
| EPS Diluted | 13.62% | 20.87% | -38.34% | -29.58% | 19.11% |
| Normalized Diluted EPS | 13.61% | 20.86% | -38.34% | -29.57% | 19.10% |
| Average Basic Shares Outstanding | 44.75% | 40.57% | 23.10% | 35.62% | 66.11% |
| Average Diluted Shares Outstanding | 44.75% | 40.57% | 23.10% | 35.62% | 66.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |